ESR1 and metastatic neoplasm: ESR1 ligand binding missense mutations are predominantly acquired during treatment with aromatase inhibitors in metastatic disease, and, after such treatment in metastatic disease, these alterations are detected in more than 50% of patients when testing circulating tumor DNA (ctDNA) (7).